-
Most Recent
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Johnson & Johnson: How Healthy Is JNJ Stock?
Johnson & Johnson (JNJ) stock has long been a mainstay of many investors' healthcare holdings. But is JNJ's future still bright?
Pfizer Inc. Stock: A Good Buy While the Pharma Industry Is Down (PFE)
Between a planned merger with Allergan and a strong pipeline of drugs, PFE stock is a solid choice at a great price.
4 Healthcare Stocks on Shaky Ground – MRK LLY AZN BMY
Biotechnology stocks have broken down, and certain pharmaceutical stocks are now following suit. Could Merck and other pharmas suffer more downside?
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Ready to Bounce!
The IBB ETF of biotech stocks has reached support levels that could spark a better bounce. Active investors should take notice.
Clovis Oncology (CLVS) Knocked Out By FDA Inquiry
Clovis Oncology Inc suffered a massive setback to its lung cancer treatment program, erasing years of gains made by CLVS stock.
Here’s Why You Should Buy More CELG Shares After Earnings Dip
Third quarter show that CELG continues to grow its business, it continues to make product people like and that Revlimid hasn't peaked yet.
Gilead Sciences, Inc. – GILD Stock Catches the Bears Off Guard Again
Biotechnology stocks as a group are not yet out of the woods, but single-name stocks like GILD stock look promising right now.
Trade of the Day: Biotech Double – Mannkind (MNKD) and PDL BioPharma (PDLI)
Biotech stocks got hit hard in recent weeks as concerns about prescription drug prices mounted.
Abbott Laboratories Remain a Long-Term Hold (ABT)
ABT stock offers a reliable way to tap into the growth in emerging markets plus the heart stents and adult nutritional beverages markets.
AZN: Why AstraZeneca’s Current Dip Is a Buying Opportunity
Astrazeneca has been investing aggressively in immuno-oncology, which will make AZN stock much more attractive in the long run.
3 of the Best Actively Managed Fidelity Funds
Fidelity funds offer a broad selection of low-cost, no-load, actively-managed funds. Here are 3 of their best.
AMGN Stock: The Dark Underbelly of Amgen Earnings
Amagen reported a stellar-looking earnings report, but a lot of its revenue increases were due to price hikes and not higher adoption.
Big Opportunities in Big Pharma
There’s a lot going on in biotech right now, which means there are plenty of opportunities worth looking into.
GILD Stock: 2 Big Things You Should Know About Gilead Sciences
Gilead is walloping its biotech peers on its way to cornering the HCV market. With improving sales, income and better cash management, GILD stock is a reliable long-term investment.
The Big Winners in Teva’s Acquisition of Allergan Generics
Teva and Allergan benefit the most from the $40 billion deal, but prospects remain bright for Mylan, Perrigo and, indeed, the wider sector.
Short the IBB ETF While Pressure Builds
The price action of the Nasdaq Biotechnology Index (IBB) is flashing warning signs for large-cap biotech.
